Endometrial Hyperplasia

Obstet Gynecol. 2022 Dec 1;140(6):1061-1075. doi: 10.1097/AOG.0000000000004989. Epub 2022 Nov 2.


The objectives of this Clinical Expert Series on endometrial hyperplasia are to review the etiology and risk factors, histologic classification and subtypes, malignant progression risks, prevention options, and to outline both surgical and nonsurgical treatment options. Abnormal uterine and postmenopausal bleeding remain the hallmark of endometrial pathology, and up to 10-20% of postmenopausal bleeding will be either hyperplasia or cancer; thus, immediate evaluation of any abnormal bleeding with either tissue procurement for pathology or imaging should be undertaken. Although anyone with a uterus may develop atypical hyperplasia, also known as endometrial intraepithelial neoplasia (EIN), genetic predispositions (eg, Lynch syndrome), obesity, chronic anovulation, and polycystic ovarian syndrome all markedly increase these risks, whereas use of oral contraceptive pills or progesterone-containing intrauterine devices will decrease the risk. An EIN diagnosis carries a high risk of concomitant endometrial cancer or eventual progression to cancer in the absence of treatment. The definitive and curative treatment for EIN remains hysterectomy; however, the obesity epidemic, the potential desire for fertility-sparing treatments, the recognition of varying rates of malignant transformation, medical comorbidities, and an aging population all may factor into decisions to employ nonsurgical treatment modalities.

Publication types

  • Review

MeSH terms

  • Aged
  • Carcinoma in Situ*
  • Endometrial Hyperplasia* / diagnosis
  • Endometrial Hyperplasia* / etiology
  • Endometrial Hyperplasia* / therapy
  • Endometrial Neoplasms* / diagnosis
  • Endometrial Neoplasms* / epidemiology
  • Endometrial Neoplasms* / etiology
  • Female
  • Humans
  • Hyperplasia / complications
  • Obesity / complications
  • Obesity / epidemiology
  • Uterine Hemorrhage / etiology